Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a trial.

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...

The fine chemicals industry is turning increasingly to biological synthesis routes to fulfill the rapidly growing demand for enantiomerically pure pharmaceuticals 1. The rapidly changing product ...

My ideal client may feel overwhelmed by life’s ups and downs, carrying past trauma or emotional wounds that make it hard to move forward. They may struggle with anxiety, depression, sleep difficulties ...

This private family home embodies everything we love about Queensland living - relaxed, sun-drenched, and made for easy entertaining. Positioned on a generous 521m² block and framed by lush, manicured ...